Skip to main content

Advertisement

SpringerLink
Log in

Treatment considerations in neuropathic pain

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Neuropathy is a relatively common source of acute and chronic pain. Emerging evidence suggests several pathophysiological mechanisms underlying the neuropathic pain associated with various disorders. Antidepressants and anticonvulsants have largely been the mainstay of treatment. Pharmacologic treatment of neuropathy frequently requires use of multiple medications. Ideally, the selection of which medications to use should be based on targeting the multiple pathophysiologic mechanisms contributing to neuropathic pain transmission. Psychological variables may play a role in predisposing patients to chronic neuropathy after acute illness. In addition, comorbid conditions, especially depression, can complicate the presentation, clinical course, and response to treatment of patients with chronic pain. Treatment of depression may be essential to fully enlist the chronic neuropathic pain patient in comprehensive pain management and rehabilitative approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. International Association for the Study of Pain: IASP pain terminology. In Classification of Chronic Pain. Edited by Merskey H, Bogduk N. Seattle, Washington: IASP Press; 1994:209–214.

    Google Scholar 

  2. Baron R: Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 2000, 16(Suppl):12–20. This article reviews the neural mechanisms in neuropathic pain and correlates them to symptoms.

    Article  Google Scholar 

  3. Jensen TS: Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002, 6(Suppl A):61–68.

    Article  PubMed  CAS  Google Scholar 

  4. Offenbaecher M, Ackenheil M: Current trends in neuropathic pain treatments. CNS Spectr 2005, 10:285–297.

    PubMed  Google Scholar 

  5. Carter GT, Galer BS: Advances in the management of neuropathic pain. Phys Med Rehabil Clin N Am 2001, 12:447–459.

    PubMed  CAS  Google Scholar 

  6. Berger A, Dukes EM, Oster G: Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004, 5:143–149.

    Article  PubMed  Google Scholar 

  7. Backonja MM, Serra J: Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med 2004, 5(Suppl 1):28–47.

    Article  Google Scholar 

  8. Serpell MG, Neuropathic Pain Study Group: Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002, 99:557–566.

    Article  PubMed  CAS  Google Scholar 

  9. McQuay HJ, Tramer M, Nye BA, et al.: A systematic review of antidepressants in neuropathic pain. Pain 1996, 68:217–227.

    Article  PubMed  CAS  Google Scholar 

  10. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83:389–400. This article calculates the number needed to treat for antidepressants used as analgesics in neuropathic pain trials and discusses mechanisms of action.

    Article  PubMed  CAS  Google Scholar 

  11. Woolf CJ, Bennett GJ, Doherty M, et al.: Toward a mechanism-based classification of pain? Pain 1998, 77:227–229.

    Article  PubMed  CAS  Google Scholar 

  12. Markman JD, Dworkin RH: Ion channel targets and treatment efficacy in neuropathic pain. J Pain 2006, 7(Suppl 1):38–47.

    Article  CAS  Google Scholar 

  13. Galer BS: Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995, 45(Suppl 9):17–25.

    Google Scholar 

  14. Collins SL, Moore RA, McQuay HJ, Wiffen P: Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000, 20:449–458.

    Article  PubMed  CAS  Google Scholar 

  15. McQuay HJ: Neuropathic pain: evidence matters. Eur J Pain 2002, 6(Suppl A):11–18.

    Article  PubMed  Google Scholar 

  16. Lynch ME: Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001, 26:30–36.

    PubMed  CAS  Google Scholar 

  17. Fields HL, Basbaum AI: Central nervous system mechanisms of pain modulation. In Textbook of Pain, edn 4. Edited by Wall PD, Melzack R. Edinburgh: Churchill Livingstone; 1999:309–329. A comprehensive review of the central nervous system modulators of pain transmission.

    Google Scholar 

  18. Baba H, Shimoji K, Yoshimura M: Norepinephrine facilitates inhibitory transmission in substantia gelatinosa of adult rat spinal cord (part 1): effects on axon terminals of GABAergic and glycinergic neurons. Anesthesiology 2000, 92:473–484.

    Article  PubMed  CAS  Google Scholar 

  19. Kawasaki Y, Kumamoto E, Furue H, Yoshimura M: Alpha 2 adrenoceptor-mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons. Anesthesiology 2003, 98:682–689.

    Article  PubMed  CAS  Google Scholar 

  20. Obata H, Saito S, Koizuka S, et al.: The monoaminemediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 2005, 100:1406–1410.

    Article  PubMed  CAS  Google Scholar 

  21. Onghena P, Van Houdenhove B: Antidepressantinduced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992, 49:205–219.

    Article  PubMed  CAS  Google Scholar 

  22. Rowbotham MC, Reisner LA, Davies PS, Fields HL: Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial. J Pain 2005, 6:741–746.

    Article  PubMed  CAS  Google Scholar 

  23. Goldstein DJ, Lu Y, Detke MJ, et al.: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005, 116:109–118.

    Article  PubMed  CAS  Google Scholar 

  24. Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004, 110:697–706.

    Article  PubMed  CAS  Google Scholar 

  25. Sindrup SH, Bach FW, Madsen C, et al.: Venlafaxine versus imipramine in painful polyneuropathy--a randomized, controlled trial. Neurology 2003, 60:1284–1289.

    PubMed  CAS  Google Scholar 

  26. Leo RJ: Concise Guide to Pain Management for Psychiatrists. Washington, DC: American Psychiatric Publishing Inc.; 2003.

    Google Scholar 

  27. Max MB: Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol 1994, 35(Suppl):50–53.

    Article  Google Scholar 

  28. Max MB, Lynch SA, Muir J, et al.: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326:1250–1256.

    Article  PubMed  CAS  Google Scholar 

  29. Sussman N: SNRI’s versus SSRI’s: mechanisms of action in treating depression and painful physical symptoms. Prim Care Companion J Clin Psychiatry 2003, 5(Suppl 7):19–26.

    Google Scholar 

  30. LaRoche SM, Helmers SL: The new antiepileptic drugs. JAMA 2004, 291:605–614.

    Article  PubMed  CAS  Google Scholar 

  31. Pappagallo M: Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003, 25:2506–2538. This article reviews the empirical data for the use of anticonvulsants in neuropathic pain and migraine.

    Article  PubMed  CAS  Google Scholar 

  32. Vinik A: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005, 90:4936–4945.

    Article  PubMed  CAS  Google Scholar 

  33. Guay DR: Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 2003, 1:18–37.

    Article  PubMed  CAS  Google Scholar 

  34. Novak V, Kanard R, Kissel JT, Mendell JR: Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res 2001, 11:357–361.

    Article  PubMed  CAS  Google Scholar 

  35. Khoromi S, Patsalides A, Parada S, et al.: Topiramate in chronic lumbar radicular pain. J Pain 2005, 6:829–836.

    Article  PubMed  CAS  Google Scholar 

  36. Bowsher D: The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997, 13:327–331.

    Article  PubMed  CAS  Google Scholar 

  37. Dahl JB, Mathiesen O, Moiniche S: ’Protective premedication’: an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain. Acta Anaesthesiol Scand 2004, 48:1130–1136.

    Article  PubMed  CAS  Google Scholar 

  38. Chandramouli J: Newer anticonvulsant drugs in neuropathic pain and bipolar disorder. J Pain Palliat Care Pharmacother 2002, 16:19–37.

    Article  PubMed  Google Scholar 

  39. Schmader KE: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350–354.

    Article  PubMed  Google Scholar 

  40. Haythornthwaite JA, Benrud-Larson LM: Psychological aspects of neuropathic pain. Clin J Pain 2000, 16(Suppl):101–105.

    Google Scholar 

  41. Burns JW, Johnson BJ, Mahoney N, et al.: Cognitive and physical capacity process variables predict long-term outcome after treatment of chronic pain. J Consult Clin Psychol 1998, 66:434–439.

    Article  PubMed  CAS  Google Scholar 

  42. Holzberg AD, Robinson ME, Geisser ME, Gremillion HA: The effects of depression and chronic pain on psychosocial and physical functioning. Clin J Pain 1996, 12:118–125.

    Article  PubMed  CAS  Google Scholar 

  43. DiMatteo MR, Lepper HS, Croghan TW: Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101–2107.

    Article  PubMed  CAS  Google Scholar 

  44. Bril V: Status of current clinical trials in diabetic polyneuropathy. Can J Neurol Sci 2001, 28:191–198.

    PubMed  CAS  Google Scholar 

  45. Medina-Santillan R, Morales-Franco G, Espinoza-Raya J, et al.: Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex, preliminary results. Proc West Pharmacol Soc 2004, 47:109–112.

    PubMed  CAS  Google Scholar 

  46. Kolke H, Iijima M, Mori K, et al.: Postgastrectomy polyneuropathy with thiamine deficiency is identical to beriberi neuropathy. Nutrition 2004, 20:961–966.

    Article  CAS  Google Scholar 

  47. Abresch RT, Jensen MP, Carter GT: Health-related quality of life in peripheral neuropathy. Phys Med Rehabil Clin N Am 2001, 12:461–472.

    PubMed  CAS  Google Scholar 

  48. Ansari A: The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 2000, 7:257–277.

    Article  PubMed  CAS  Google Scholar 

  49. Gerner P, Mujtaba M, Sinnott CJ, Wang GK: Amitriptyline versus bupivacaine in rat sciatic nerve blockade. Anesthesiology 2001, 94:661–667.

    Article  PubMed  CAS  Google Scholar 

  50. Sindrup SH, Bjerre U, Dejgaard A, et al.: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992, 52:547–552.

    Article  PubMed  CAS  Google Scholar 

  51. Sindrup SH, Gram LF, Brosen K, et al.: The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990, 42:135–144.

    Article  PubMed  CAS  Google Scholar 

  52. Ohanyon M, Roth T: Prevalence of restless legs syndrome and periodic movement disorder in the general population. J Psychosom Res 2002, 53:547–554.

    Article  Google Scholar 

  53. Semenchuk MR, Sherman S, Davis B: Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001, 57:1583–1588.

    PubMed  CAS  Google Scholar 

  54. Yerby MS: Special considerations for women with epilepsy. Pharmacotherapy 2000, 20(Suppl 8):159–170.

    Article  Google Scholar 

  55. Sang CN, Booher S, Gilron I, et al.: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002, 96:1053–1061.

    Article  PubMed  CAS  Google Scholar 

  56. Eide PK, Jorum E, Stubhaug A, et al.: Relief of post-herpetic neuralgia with the N-methyl-aspartic acid receptor antagonist ketamine: a double-blind cross-over comparison with morphine and placebo. Pain 1994, 58:347–354.

    Article  PubMed  CAS  Google Scholar 

  57. Eisenberg E, Kleiser A, Dotort A, et al.: The NMDA (Nmethyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a doubleblind, placebo-controlled study. Eur J Pain 1998, 2:321–327.

    Article  CAS  PubMed  Google Scholar 

  58. Enarson MC, Hays H, Woodroffe MA: Clinical experience with oral ketamine. J Pain Symptom Manage 1999, 17:384–386.

    Article  PubMed  CAS  Google Scholar 

  59. Wallace MS, Rowbotham MC, Katz NP, et al.: A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002, 59:1694–1700.

    PubMed  CAS  Google Scholar 

  60. McCleane G: Topical capsaicin of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol 2000, 49:574–579.

    Article  PubMed  CAS  Google Scholar 

  61. Meier T, Wasner G, Faust M, et al.: Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003, 106:151–158.

    Article  PubMed  CAS  Google Scholar 

  62. Wallace MS, Magnuson S, Ridgeway B: Oral mexiletine in the treatment of neuropathic pain. Reg Anesth Pain Med 2000, 25:459–467.

    Article  PubMed  CAS  Google Scholar 

  63. Resnick HE, Vinik AI, Schwartz AV, et al.: Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age: the women’s health and aging study. Diabetes Care 2000, 23:1642–1647.

    Article  PubMed  CAS  Google Scholar 

  64. Nelson ME, Fiatarone MA, Morganti CM, et al.: Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. JAMA 1994, 272:1909–1914.

    Article  PubMed  CAS  Google Scholar 

  65. Katz J, McDermott MP, Cooper EM, et al.: Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain 2005, 6:782–790.

    Article  PubMed  Google Scholar 

  66. Morley S, Eccleston C, Williams A: Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1999, 80:1–13.

    Article  PubMed  CAS  Google Scholar 

  67. Gainer MJ: Hypnotherapy for reflex sympathetic dystrophy. Am J Clin Hypn 1992, 34:227–232.

    PubMed  CAS  Google Scholar 

  68. Sherman RA, Gall N, Gormly J: Treatment of phantom limb pain with muscular relaxation training to disrupt the pain-anxiety-tension cycle. Pain 1979, 6:47–55.

    Article  PubMed  CAS  Google Scholar 

  69. Follett KA: Neurosurgical techniques. In Pain Medicine and Management. Edited by Wallace MS, Staats PS. New York: McGraw-Hill Companies Inc.; 2005:301–309.

    Google Scholar 

  70. Abuaisha BB, Costanzi JB, Boulton AJM: Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998, 39:115–121.

    Article  PubMed  CAS  Google Scholar 

  71. Shlay JC, Chaloner K, Max MB, et al.: Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy--a randomized controlled trial. JAMA 1998, 280:1590–1595.

    Article  PubMed  CAS  Google Scholar 

  72. Lefaucheur JP, Drouot X, Keravel Y, Nguyen JP: Pain relief induced by repetitive transcranial magnetic stimulation of precentral cortex. Neuroreport 2001, 12:2963–2965.

    Article  PubMed  CAS  Google Scholar 

  73. Fox A, Kesingland A, Gentry C, et al.: The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001, 92:91–100.

    Article  PubMed  CAS  Google Scholar 

  74. Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004, 329:253–260.

    Article  PubMed  CAS  Google Scholar 

  75. Puozzo C, Panconi E, Deprez D: Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 2002, 17(Suppl 1):25–35.

    Google Scholar 

  76. Obata H, Conklin D, Eisenach JC: Spinal noradrenaline transporter inhibition by reboxetine and xen2174 reduces tactile hypersensitivity after surgery in rats. Pain 2005, 113:271–276.

    Article  PubMed  CAS  Google Scholar 

  77. Canavero S, Bonicalzi V, Paolotti R: Reboxetine for central pain: a single-blind prospective study. Clin Neuropharmacol 2002, 25:238–239.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Erie County Medical Center, 462 Grider Street, 14215, Buffalo, NY, USA

    Raphael J. Leo MD

Authors
  1. Raphael J. Leo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leo, R.J. Treatment considerations in neuropathic pain. Curr Treat Options Neurol 8, 389–400 (2006). https://doi.org/10.1007/s11940-006-0028-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-006-0028-4

Keywords

Search

Navigation